$0.37
(Market cap
$1,334 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
4.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.5 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.5
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-3.4
-
Face value
--
-
Shares outstanding
61,458,046
10 Years Aggregate
CFO
$-368.93 Mln
EBITDA
$-764.18 Mln
Net Profit
$-192.62 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cullinan Oncology LLC (CGEM)
| 113.2 | 26.0 | 34.2 | 192.7 | 26.5 | -5.7 | -- |
|
BSE Sensex*
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Cullinan Oncology LLC (CGEM)
| -15.0 | 19.4 | -3.4 | -31.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cullinan Oncology LLC (CGEM)
|
22.1 | 1,333.6 | 0.0 | -204.7 | -- | -56 | -- | 4.5 |
| 82.4 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 263.0 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 70.9 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.6 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 106.5 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 359.4 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 540.0 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 594.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 350.3 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Cullinan Oncology LLC (CGEM)
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune... diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Read more
-
President, CEO & Director
Mr. Nadim Ahmed
-
President, CEO & Director
Mr. Nadim Ahmed
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Cullinan Oncology LLC (CGEM)
What is the current share price of Cullinan Oncology LLC (CGEM) Today?
The share price of Cullinan Oncology LLC (CGEM) is $22.07 (NASDAQ) as of 31-Aug-2026 16:02 EDT. Cullinan Oncology LLC (CGEM) has given a return of 26.55% in the last 3 years.
What is the current PB & PE ratio of Cullinan Oncology LLC (CGEM)?
Since, TTM earnings of Cullinan Oncology LLC (CGEM) is negative, P/E ratio is not available.
The P/B ratio of Cullinan Oncology LLC (CGEM) is 4.52 times as on 28-Aug-2026, a 13 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-2.79 |
1.50 |
2024 |
-4.26 |
1.21 |
2023 |
-2.85 |
0.96 |
2022 |
4.34 |
0.90 |
2021 |
-10.35 |
1.58 |
What is the 52 Week High and Low of Cullinan Oncology LLC (CGEM)?
The 52-week high and low of Cullinan Oncology LLC (CGEM) are Rs 23.19 and Rs 5.68 as of 01-Sep-2026.
What is the market cap of Cullinan Oncology LLC (CGEM)?
Cullinan Oncology LLC (CGEM) has a market capitalisation of $ 1,334 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Cullinan Oncology LLC (CGEM)?
Before investing in Cullinan Oncology LLC (CGEM), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.